Sarepta Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
So thanks for being here everybody. We're going to get started with the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley, and pleased to have Sarepta.
Just quickly before I get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.
So very pleased to have with me Doug Ingram, who is the President and CEO of Sarepta. Doug, I don't know if you want to make any opening comments, but if not, we'll jump right in.
Sure. Well first, let me say this because I've been reminded I have to mention our forward-looking statements. Obviously, we'll be talking about things that are going to happen in the future. There
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |